Clinical trial NCT03124199 - References

Bacterial Infection Due to Helicobacter Pylori (H. Pylori) — Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

Citation(s)

•   Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H
  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol. 2004 Jun 1;10(11):1656-8.
•   Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP; Hp Study Group of the Asociación Española de Gastroenterología
  Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005 Aug;100(8):1696-701.
•   Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A
  Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther. 2002 Jul;16(7):1269-75.
•   Egan BJ, Marzio L, O'Connor H, O'Morain C
  Treatment of Helicobacter pylori infection. Helicobacter. 2008 Oct;13 Suppl 1:35-40. doi: 10.1111/j.1523-5378.2008.00639.x.
•   Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J
  [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol. 2013 May;36(5):340-74. doi: 10.1016/j.gastrohep.2013.01.011. Epub 2013 Apr 18. Spanish.
•   Gisbert JP, Domínguez-Muñoz A, Domínguez-Martín A, Gisbert JL, Marcos S
  Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am J Gastroenterol. 2005 Sep;100(9):1935-40.
•   Gisbert JP, Pajares R, Pajares JM
  Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter. 2007 Nov;12 Suppl 2:50-8. Review.
•   Graham DY, Fischbach L
  Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757. Epub 2010 Jun 4. Review.
•   Graham DY
  Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1032-6. doi: 10.1016/j.cgh.2010.07.002. Epub 2010 Jul 23. Erratum in: Clin Gastroenterol Hepatol. 2011 Mar;9(3):280.
•   Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S
  Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol. 2004 Mar 1;10(5):668-71.
•   Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M
  Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol Ther. 2003 Apr;17(8):1065-74.
•   Howden CW, Hunt RH
  Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998 Dec;93(12):2330-8.
•   Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG
  Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000 Dec;95(12):3393-8.
•   Laine L, Suchower L, Frantz J, Connors A, Neil G
  Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998 Nov;93(11):2106-12.
•   Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group
  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.
•   Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, Rossi P, Gurnari M, Caracciolo F, Zippi M, Pica R
  2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter. 2006 Dec;11(6):562-8.
•   Vakil N, Hahn B, McSorley D
  Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.
•   Vakil N, Lanza F, Schwartz H, Barth J
  Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004 Jul 1;20(1):99-107.
•   Veldhuyzen Van Zanten S, Machado S, Lee J
  One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1381-7.
•   Yakoob J, Abid S, Abbas Z, Jafri SN
  Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci. 2010;67(4):197-201.

Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection

Details for clinical trial NCT03124199